1. The European Lead Factory: An updated HTS compound library for innovative drug discovery
- Author
-
Jean-Yves Ortholand, Jon S.B. de Vlieger, Herman van Vlijmen, and Volkhart Mj Li
- Subjects
0301 basic medicine ,Knowledge management ,Drug Industry ,Structural diversity ,Small Molecule Libraries ,03 medical and health sciences ,0302 clinical medicine ,Lead (geology) ,High throughput screening ,Library synthesis ,Drug Discovery ,Humans ,Pharmacology ,Compound library ,business.industry ,Drug discovery ,Public–private partnership ,High-Throughput Screening Assays ,Europe ,030104 developmental biology ,Pharmaceutical Preparations ,Therapeutic Area ,030220 oncology & carcinogenesis ,Factory (object-oriented programming) ,Business ,human activities ,Diversity (business) - Abstract
Through the European Lead Factory model, industry-standard high-throughput screening and hit validation are made available to academia, small and medium-sized enterprises, charity organizations, patient foundations, and participating pharmaceutical companies. The compound collection used for screening is built from a unique diversity of sources. It brings together compounds from companies with different therapeutic area heritages and completely new compounds from library synthesis. This generates structural diversity and combines molecules with complementary physicochemical properties. In 2019, the screening library was updated to enable another 5 years of running innovative drug discovery projects. Here, we investigate the physicochemical and diversity properties of the updated compound collection. We show that it is highly diverse, drug-like, and complementary to commercial screening libraries.
- Published
- 2021